drugset / Trial / NCT02344550

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

NCT02344550

Phase 2 Completed 137 enrolled Asan Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of addition of everolimus to letrozole with LHRH agonist in premenopausal metastatic breast cancer patients who failed to tamoxifen treatment.

Timeline

Start
2014-01
Primary completion
2018-10
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral
Background Letrozole Other / unclassified 2.5 mg Oral
Background Leuprolide Other / unclassified 3.75 mg Subcutaneous

Indications